Navigation Links
Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
Date:1/7/2008

et exclusivity of the product for seven years, in addition to other incentives.

AST-120 was in-licensed from Kureha Corporation, Japan in 2005 and is currently being studied in a Phase 3 trial in Fistulizing Crohn's disease.

About Ocera Therapeutics, Inc.

Ocera Therapeutics, Inc. is a privately held biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Ocera is based in San Diego and is pursuing the development of AST-120 in Crohn's disease, Pouchitis and conducting proof of concept trials in other gastrointestinal and liver diseases including, Hepatic Encephalopathy, Irritable Bowel Syndrome and Proton Pump Inhibitor-resistant Gastroesophageal Reflux Disease. Ocera Therapeutics has raised $26.5 million dollars in venture financing from Domain Associates, Sofinnova Ventures and Thomas, McNerney & Partners. Additional information on the Company can be found at http://www.oceratherapeutics.com.

For more information on Pouchitis, visit the Crohn's and Colitis Foundation of America website at http://www.ccfa.org.

Media Contact: Company Contact:

Melissa Hill Laurent Fischer

Porter Novelli Life Sciences Ocera Therapeutics, Inc.

619-849-6004 858-436-3901

mhill@pnlifesciences.com lfischer@ocerainc.com


'/>"/>
SOURCE Ocera Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. National Patient Safety Foundation Partners with Vocera Communications
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...class of drugs based on a widely used anticancer d...g effects in the laboratory and in mice, according... interesting for the treatment of these tumors. //...rea were extremely active in blocking the same cel...
... Cipro, Cipro. That's been the mantra of the media...usands who weren't -- clamor for the potent antibi...r cheaper and widely available medications can be ...rug: penicillin. Although alternatives exist, Cipr...
...erimental anti-cancer drug has shown effectiveness...ng to a new report. Researchers say the drug proba...be useful for treating other types of cancer. Dr. ...Bethesda, Maryland, and colleagues tested the drug...
...ox, a highly contagious virus that kills at least ...survive, was eradicated from the globe more than t...variola virus, which causes the disease, and store..., and Moscow, Russia. A smallpox attack is just on...
Other Medicine News:
(Date:9/6/2008)...monstrate Safety and Efficacy of First-in-Class Ne...he Treatment of Acute Migraine, LONDON, Sept. 6 /...nnovative biotechnology company focusing on therap...d Phase II results of its lead compound COL-144,in...ated that COL-144 was,safe and effective in reliev...
(Date:9/5/2008)... Va., Sept. 5 /- CEL-SCI Co...esented new rheumatoid arthritis data,at the Marcu... The data,presented by Dr. Daniel Zimmerman, Seni... of CEL-SCI, indicate that CEL-SCI,s rheumatoid,ar...ermanent tissue damage,caused by rheumatoid arthri...
(Date:9/4/2008)...NE, Australia, Sept. 4 /- Cytopia Lim...ing enrolment for its Phase Ib/II,study of CYT997,...r agent,in patients with an aggressive form of br..., The GBM clinical trial is the first Phase II ef...ations for the company and the second in its,suite...
(Date:9/4/2008)...a Published in ,The Lancet, and Presented at ESC C...esults from a new international,study, the GISSI H...ose of,omega-3 acid ethyl esters reduced all cause...lar reasons in patients with chronic heart,failure...ne version of ,The,Lancet, and were presented at t...
Breaking Medicine Technology:Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008 2Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 2Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 4Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Low Back Disorders Chapter Released 9839 1Low Back Disorders Chapter Released 9839 2Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday February 06 2008 9837 1Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday February 06 2008 9837 2Abortion Opponents in 59 Cities Prepare Focused 40 Day Campaign to Counter Impact of Roe v Wade 9835 1Abortion Opponents in 59 Cities Prepare Focused 40 Day Campaign to Counter Impact of Roe v Wade 9835 2Fertility Experts 3A Winter Waistlines a Swelling Problem for Indianians Trying to Get Pregnant 9833 1Fertility Experts 3A Winter Waistlines a Swelling Problem for Indianians Trying to Get Pregnant 9833 2Fertility Experts 3A Winter Waistlines a Swelling Problem for Indianians Trying to Get Pregnant 9833 3
...26, 2007 - Study results show,that elevated lipopr...diovascular-specific inflammatory enzyme associate...ck and stroke, is,especially predictive of heart d...e--a serious medical condition that affects nearly...sented yesterday,at the American College of Cardio...
...Problem of Antibiotic Resistance,Published in Natu...ch 26, 2007 /PRNewswire/ --,Inimex Pharmaceuticals...e system trigger to cure infections without causin...shed in the April 2007,issue of Nature Biotechnolo...ex and its,co-founders Dr. Bob Hancock and Dr. Bre...
Other Medicine Technology:Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients 2Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients 3Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation 2
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use.
Used for stone manipulation and removal in the urinary tract. Enhanced wire strength permits the basket to expand the ureter more readily than standard flat-wire designs. The Unidex handle facilitate
...d for stone manipulation and removal in the urinar... to retain its shape following extreme torsion. Th...ture by allowing the basket to open at the base of...ign reduces the likelihood of mucosal damage and p...
Used to establish and maintain nephrostomy drainage following pyeloplasty. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; stent must not r
Medicine Products: